Patents matching “formulation”

US 11096954

Bisphosphocin gel formulations and uses thereof

Lakewood Amedex, Inc. · Granted Aug 24, 2021 · Expires Aug 19, 2041

US 11084865

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Aug 10, 2021 · Expires Aug 5, 2041

US 11077079

GHB formulation and method for its manufacture

Jazz Pharmaceuticals Ireland Limited · Granted Aug 3, 2021 · Expires Jul 29, 2041

US 11077114

Stabilized formulations of CNS compounds

Supernus Pharmaceuticals, Inc. · Granted Aug 3, 2021 · Expires Jul 29, 2041

US 11077077

Therapeutic compounds, formulations, and uses thereof

Tvardi Therapeutics, Inc. · Granted Aug 3, 2021 · Expires Jul 29, 2041

US 11071780

Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab

REGENERON PHARMACEUTICALS, INC. · Granted Jul 27, 2021 · Expires Jul 22, 2041

US 11066458

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Jul 20, 2021 · Expires Jul 15, 2041

US 11066656

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Jul 20, 2021 · Expires Jul 15, 2041

US 11059896

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Jul 13, 2021 · Expires Jul 8, 2041

US 11058671

Formulations and methods of manufacturing formulations for use in colonic evacuation

RedHill Biopharma Ltd. · Granted Jul 13, 2021 · Expires Jul 8, 2041

US 11045466

Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

Platform Brightworks Two, Ltd. · Granted Jun 29, 2021 · Expires Jun 24, 2041

US 11041149

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Jun 22, 2021 · Expires Jun 17, 2041

US 11040011

Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same

Pacira Pharmaceuticals, Inc. · Granted Jun 22, 2021 · Expires Jun 17, 2041

US 11033626

Progesterone formulations having a desirable pk profile

Compass Therapeutics LLC · Granted Jun 15, 2021 · Expires Jun 10, 2041

US 11026898

Eutectic formulations of cyclobenzaprine hydrochloride

TONIX PHARMA LIMITED · Granted Jun 8, 2021 · Expires Jun 3, 2041

US 11026939

High dosage valbenazine formulation and compositions, methods, and kits related thereto

Neurocrine Biosciences, Inc. · Granted Jun 8, 2021 · Expires Jun 3, 2041

US 11020459

Factor VIII formulations

UNIVERSITY OF CONNECTICUT · Granted Jun 1, 2021 · Expires May 27, 2041

US 11021576

Polymeric stabilizing formulations

Nano Precision Medical, Inc. · Granted Jun 1, 2021 · Expires May 27, 2041

US 11020485

Pharmaceutical formulation

Semnur Pharmaceuticals, Inc. · Granted Jun 1, 2021 · Expires May 27, 2041

US 11020403

Precipitation resistant small molecule drug formulations

XERIS PHARMACEUTICALS, INC. · Granted Jun 1, 2021 · Expires May 27, 2041

US 11013809

Sustained delivery formulations of risperidone compound

Indivior UK Limited · Granted May 25, 2021 · Expires May 20, 2041

US 11013787

Sustained release formulation of interleukin-10 for wound treatment and related methods

THE REGENTS OF THE UNIVERSITY OF COLORADO FOR AND ON BEHALF OF THE UNIVERSITY OF COLORADO DENVER · Granted May 25, 2021 · Expires May 20, 2041

US 11013808

Clinical formulations

Astellas Institute for Regenerative Medicine · Granted May 25, 2021 · Expires May 20, 2041

US 11001551

Controlled release pharmaceutical formulations

United Therapeutics Corporation · Granted May 11, 2021 · Expires May 6, 2041